# Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer

> **NCT00732082** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Gemcitabine
- **BIOLOGICAL:** LAG-3

## Key facts

- **NCT ID:** NCT00732082
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2010-02
- **Final completion:** 2012-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Company manufacturing study drug was unable to continue production.
- **Last updated:** 2013-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732082, "Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00732082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*